logo
Twitter
Discord
Email
logo
Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

NASDAQ•AUPH
CEO: Mr. Peter S. Greenleaf M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-09-03
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Contact Information
118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada
250-744-2487
www.auriniapharma.com
Market Cap
$1.73B
P/E (TTM)
30.2
17.1
Dividend Yield
--
52W High
$13.54
52W Low
$6.55
52W Range
95%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2025 Data

Revenue

$70.01M+22.41%
4-Quarter Trend

EPS

$0.15+2900.00%
4-Quarter Trend

FCF

$44.14M+179.75%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Product Sales Strong Growth Net product sales reached $126.5M for six months, marking a $23.4M increase over prior period sales, driven by LN market penetration.
Income Swings to Profit Net income $44.9M for six months, a significant positive swing from $10.0M net loss reported last year, before tax expense.
Operating Cash Flow Positive Cash provided by operations totaled $45.5M for six months, reversing prior period cash usage of $2.8M, excluding restructuring payments.
Share Repurchase Plan Increased Board approved additional $150M for Share Repurchase Plan on July 31, 2025, following $90.8M spent in the first half.

Risk Factors

LUPKYNIS Patent Challenges Received multiple Paragraph IV notices alleging invalidity of 2037 Patents; company intends to vigorously enforce intellectual property rights.
Adverse US Economic Laws Potential US government measures on pharmaceutical imports could materially impact business operations and international supply chain dynamics.
Noncurrent Liability Increase Deferred compensation and other noncurrent liabilities grew to $12.0M as of June 30, 2025, up from $9.4M at December 31, 2024.

Outlook

Aritinercept Clinical Studies Planned Plans to initiate clinical studies for aritinercept in at least two autoimmune diseases during the second half of the current year.
SG&A Expense Lower Expected Expect SG&A expense to remain lower in 2025 compared to 2024, realizing full benefits of strategic restructuring efforts completed in H1.
Funding Operations From Cash Expects to fund future operations using existing cash or cash generated from operations; may raise additional capital if necessary.

Peer Comparison

Revenue (TTM)

Novavax, Inc.NVAX
$1.08B
+31.1%
Harmony Biosciences Holdings, Inc.HRMY
$772.53M
+17.7%
BioCryst Pharmaceuticals, Inc.BCRX
$557.51M
+45.9%

Gross Margin (Latest Quarter)

Zymeworks Inc.ZYME
100.0%
+13.1 pp
BioCryst Pharmaceuticals, Inc.BCRX
98.3%
-0.1 pp
Syndax Pharmaceuticals, Inc.SNDX
96.6%
+1263.4 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RCUS$2.10B-6.0-69.8%10.1%
EWTX$1.93B-12.7-30.6%0.7%
AUPH$1.73B30.216.7%16.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+1.1%
Moderate Growth
4Q Net Income CAGR
+14.5%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $70.01M+22.4%
    |
    EPS: $0.15+2900.0%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $62.47M+24.2%
    |
    EPS: $0.17-327.9%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $235.13M+34.0%
    |
    EPS: $0.04+107.4%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $67.77M+24.3%
    |
    EPS: $0.10-206.3%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $57.19M+37.8%
    |
    EPS: $0.01-106.2%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $50.30M+46.2%
    |
    EPS: $-0.07-58.6%
    Beat

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 29, 2024|
    Revenue: $175.51M+31.0%
    |
    EPS: $-0.54+28.9%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 15, 2024|Refer to amended data